SOUTH SAN FRANCISCO, Calif.,
Dec. 23, 2019 /PRNewswire/
-- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA)
today announced that it will host an investor event to discuss
expected corporate and product milestones in 2020. The event is
scheduled to take place on Tuesday, January
14, at 7 a.m. PT (10 a.m. ET) and will be simultaneously
webcast.
Portola will provide updates on
Andexxa® and Ondexxya® and its
investigational hematologic compound, the oral SYK/JAK
inhibitor cerdulatinib.
Webcast Details
To access the live investor webcast on
Tuesday, January 14, at 7 a.m. PT (10 a.m.
ET), go to the investor section of the company's website at
http://investors.portola.com. A replay will be available for 30
days.
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic conditions.
The Company's first two commercialized products are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], marketed in Europe as
Ondexxya® (andexanet alfa), and
Bevyxxa® (betrixaban). The company also is
advancing cerdulatinib, a SYK/JAK inhibitor being developed for the
treatment of hematologic cancers. Founded in 2003
in South San Francisco, California, Portola has
operations in the United States and Europe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-webcast-corporate-update-on-january-14-2020-300978499.html
SOURCE Portola Pharmaceuticals, Inc.®